Results for the substance trifluridine tipiracil

Trifluridine+tipiracil is a combination medication used in the treatment of metastatic colorectal cancer and advanced gastric cancer. Trifluridine is a nucleoside analog that interferes with DNA synthesis in tumor cells, thereby inhibiting their proliferation, while tipiracil is a thymidine phosphorylase inhibitor that increases the bioavailability of trifluridine.

This combination is administered orally in tablet form, according to a specific regimen determined by the physician. It is typically used in cases where other standard treatments have failed.

Common side effects include nausea, vomiting, diarrhea, fatigue, and a decrease in blood cell counts (myelosuppression). Regular monitoring of hematological parameters is essential to prevent severe complications.

Trifluridine+tipiracil is an important therapeutic option for patients with advanced cancer, helping to extend survival and improve their quality of life.